Surveying The Changing Multiple Sclerosis Landscape
Executive Summary
The highly competitive multiple sclerosis market is in flux. With the US launch in October 2010 of Novartis AG's Gilenya, the first oral disease-modifying therapy for MS, patients and physicians have a more convenient once-daily therapy that looks to be as efficacious as first line injectables. But uncertainty concerning Gilenya's safety- not to mention the medicine's high price tag - means ample room exists for additional products in the MS armamentarium. To better understand how prescribers view the rapidly changing MS landscape, IN VIVO and Gerson Lehman Group conducted a survey of physicians in late January.